Commencement of joint research on AI-driven drug discovery with FRONTEO. By integrating DDAIF from FRONTEO with Kaion’s antibody discovery technology DoppeLib, the project aims to establish a new drug discovery platform that seamlessly progresses from target exploration to creation and validation of antibody candidates. Expected impact on the 2026 fiscal year results is minor.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4583","jir_company_name":"Kaioon Biosscience Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-09-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4583-20260903-01.pdf","jir_short_summary":"Commencement of joint research on AI-driven drug discovery with FRONTEO. By integrating DDAIF from FRONTEO with Kaion's antibody discovery technology DoppeLib, the project aims to establish a new drug discovery platform that seamlessly progresses from target exploration to creation and validation of antibody candidates. Expected impact on the 2026 fiscal year results is minor.","jir_summary":"### Section heading\nThis news release is a business update announcing the conclusion of a joint research agreement with FRONTEO on AI-driven drug discovery. The joint research aims to establish a new drug discovery platform by integrating FRONTEO's AI-assisted drug discovery service DDAIF with Kaion's antibody drug development technology DoppeLib, advancing from target discovery to creation and validation of antibody candidates in a continuous process.\n\n### Section 2 heading\nLooking ahead, multiple themes will be pursued under the joint research, with the goal of creating and deriving bispecific antibody candidates within fiscal year 2027. At the same time, application to the IDD business is also contemplated, with expectations for long-term competitive strength and profitability.","jir_financial_highlights":"Impact on results for the fiscal year ending December 2026: Unknown (Expected to be minor)\nDate of conclusion of joint research agreement: 2026-09-03 (Unknown)\nPartner: FRONTEO (Unknown)","jir_category":"","jir_hashtags":"#KaioonBiotechnology, #AI-drivenDrugDiscovery, #bispecificantibody, #DoppeLib, #DDAIF","jir_key_figures":"Date of conclusion of joint research agreement: 2026-09-03\nImpact on 2026 fiscal year results: minor\nPartner: FRONTEO","jir_meta_title":"Kaioon Biotech: Beginning Joint Research on AI-driven Drug Discovery with FRONTEO | 2026-09-03","jir_meta_description":"Kaioon Biotech has concluded a joint research agreement with FRONTEO. By combining DDAIF and DoppeLib, antibody drug discovery is accelerated. Minor impact is expected for the 2026 fiscal year.","jir_og_title":"Kaioon Biotech: Initiating Joint Research on AI-driven Drug Discovery with FRONTEO","jir_og_description":"A joint research agreement with FRONTEO has been signed. By integrating AI-driven drug discovery hypotheses and antibody creation, bispecific antibody candidates for unmet medical needs are accelerated.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59315,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-110645","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n